Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
BJOG ; 129(5): 752-759, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34665920

RESUMO

OBJECTIVE: To describe prenatal decision-making processes and birth plans in pregnancies amenable to planning perinatal palliative care. DESIGN: Multicentre prospective observational study. SETTING: Nine Multidisciplinary Centres for Prenatal Diagnosis of the Paris-Ile-de-France region. POPULATION: All cases of major and incurable fetal anomaly eligible for TOP where limitation of life-sustaining treatments for the neonate was discussed in the prenatal period between 2015 and 2016. METHODS: Cases of congenital defects amenable to perinatal palliative care were prospectively included in each centre. Prenatal diagnosis, decision-making process, type of birth plan, birth characteristics, pregnancy and neonatal outcome were collected prospectively and anonymously. MAIN OUTCOME MEASURE: Final decision reached following discussions in the antenatal period. RESULTS: We identified 736 continuing pregnancies with a diagnosis of a severe fetal condition eligible for TOP. Perinatal palliative care was considered in 102/736 (13.9%) pregnancies (106 infants); discussions were multidisciplinary in 99/106 (93.4%) cases. Prenatal birth plans involved life-sustaining treatment limitation and comfort care in 73/736 (9.9%) of the pregnancies. The main reason for planning palliative care at birth was short-term inevitable death in 39 cases (53.4%). In all, 76/106 (71.7%) infants were born alive, and 18/106 (17%) infants were alive at last follow-up, including four with a perinatal palliative care birth plan. CONCLUSIONS: Only a small proportion of severe and incurable fetal disorders were potentially amenable to limitation of life-sustaining interventions. Perinatal palliative care may not be considered a universal alternative to termination of pregnancy. TWEETABLE ABSTRACT: Perinatal palliative care is planned in 10% of continuing pregnancies with a major and incurable fetal condition eligible for TOP.


Assuntos
Doenças Fetais , Cuidados Paliativos , Criança , Feminino , Doenças Fetais/diagnóstico , Humanos , Recém-Nascido , Assistência Perinatal , Gravidez , Diagnóstico Pré-Natal , Estudos Prospectivos
2.
Gynecol Obstet Fertil Senol ; 49(7-8): 573-579, 2021.
Artigo em Francês | MEDLINE | ID: mdl-33434748

RESUMO

OBJECTIVES: Despite the guidelines in effect, too few women in France receive folic acid supplementation. The principal objective of this study was to identify the factors associated with the inadequacy of this supplementation in the periconceptional period. The secondary objective was to assess women's knowledge about the prevention of neural tube defects (NTDs). METHODS: This study included 400 women and took place in 8 Parisian maternity. Folic acid supplementation was inadequate when started after the beginning of the pregnancy. RESULTS: Among the women questioned, 68% had inadequate folic acid supplementation. They were significantly younger (ORa= 1,8; 95% IC [1,1-2,8]), didn't had health insurance (ORa=3,9; 95% IC [1,5-10,1]), had not studied after high school (ORa=2,9; 95% IC [1,2-6,9]) and had regular gynecological care less often than the women with adequate supplementation (ORa=3,0; 95% IC [1,6-5,6]). More than half (55.5%) had insufficient knowledge of the benefits of folic acid; the factors related to this lack of knowledge were the absence of regular gynecological care and of health insurance. CONCLUSION: Individual factors associated with a lack of supplementation have been identified. These results provide health professionals and supervisors with useful information for developing strategies adapted to certain subgroups of women for better prevention of AFTN in these populations.


Assuntos
Ginecologia , Defeitos do Tubo Neural , Suplementos Nutricionais , Feminino , Ácido Fólico , França , Humanos , Defeitos do Tubo Neural/prevenção & controle , Gravidez
3.
Ultrasound Obstet Gynecol ; 55(3): 310-317, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31595578

RESUMO

OBJECTIVES: To explore the outcome of monochorionic monoamniotic (MCMA) twin pregnancies affected by twin-to-twin transfusion syndrome (TTTS). METHODS: MEDLINE and EMBASE databases were searched for studies reporting the outcome of MCMA twin pregnancies complicated by TTTS. The primary outcome was intrauterine death (IUD); secondary outcomes were miscarriage, single IUD, double IUD, neonatal death (NND), perinatal death (PND), survival of at least one twin, survival of both twins and preterm birth (PTB) before 32 weeks' gestation. Outcomes were assessed in MCMA twins affected by TTTS not undergoing intervention and in those treated with amniodrainage, laser therapy or cord occlusion. Subgroup analysis was performed including cases diagnosed before 24 weeks. Random-effects meta-analysis of proportions was used to analyze the data. RESULTS: Fifteen cohort studies, including 888 MCMA twin pregnancies, of which 44 were affected by TTTS, were included in the review. There was no randomized trial comparing the different management options in MCMA twin pregnancies complicated by TTTS. In cases not undergoing intervention, miscarriage occurred in 11.0% of fetuses, while the incidence of IUD, NND and PND was 25.2%, 12.2% and 31.2%, respectively. PTB complicated 50.5% of these pregnancies. In cases treated by laser surgery, the incidence of miscarriage, IUD, NND and PND was 19.6%, 27.4%, 7.4% and 35.9%, respectively, and the incidence of PTB before 32 weeks' gestation was 64.9%. In cases treated with amniodrainage, the incidence of IUD, NND and PND was 31.3%, 13.5% and 45.7% respectively, and PTB complicated 76.2% of these pregnancies. Analysis of cases undergoing cord occlusion was affected by the very small number of included cases. Miscarriage occurred in 19.2%, while there was no case of IUD or NND of the surviving twin. PTB before 32 weeks occurred in 50.0% of these cases. CONCLUSIONS: MCMA twin pregnancies complicated by TTTS are at high risk of perinatal mortality and PTB. Further studies are needed in order to elucidate the optimal type of prenatal treatment in these pregnancies. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.


Assuntos
Transfusão Feto-Fetal/mortalidade , Resultado da Gravidez/epidemiologia , Gravidez de Gêmeos , Gêmeos Monozigóticos/estatística & dados numéricos , Aborto Espontâneo/epidemiologia , Aborto Espontâneo/etiologia , Adulto , Âmnio , Córion , Feminino , Morte Fetal/etiologia , Transfusão Feto-Fetal/complicações , Humanos , Recém-Nascido , Mortalidade Perinatal , Gravidez , Nascimento Prematuro/epidemiologia , Nascimento Prematuro/etiologia
4.
Eur J Clin Microbiol Infect Dis ; 37(2): 265-270, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29082442

RESUMO

Group B Streptococcus (GBS) is the leading cause of neonatal infections in industrialized countries. Intrapartum antibiotic prophylaxis (IAP) given to colonized parturients is a key step for the prevention of neonatal early-onset infection. We compared the performances of Xpert® GBS polymerase chain reaction (PCR) (Cepheid, Sunnyvale, CA, USA) as a point-of-care system in labor wards to standard culture for intrapartum GBS detection. Pregnant women with a GBS-positive antenatal screening were prospectively included. A vaginal double swab was collected at the time of delivery for point-of-care Xpert® GBS PCR and GBS culture. A total of 565 pregnant women were included. Valid Xpert® GBS results were obtained for 488 (86.4%) women on the first attempt. Repeat testing improved the PCR success to 516 (91.3%) women. Among the 305 women positive for GBS by culture at delivery, only 238 (78.0%) were positive by Xpert® GBS PCR, cycle thresholds being correlated to culture quantification. Among 260 women negative for GBS culture, 56 (21.5%) were positive by Xpert® GBS PCR, including 50 where IAP was initiated before vaginal sampling. Overall, among the 565 women with GBS antenatal positive culture, only 335 (59.3%) were still positive at delivery whatever the technique used, resulting in unnecessary IAP for 40% of them. This large cohort study comparing intrapartum to antepartum GBS detection provides evidence that (i) Xpert® GBS PCR might be a valuable solution for intrapartum GBS detection compared to culture-based strategies and (ii) laboratory training of non-specialized staff is mandatory to reach the performances required for point-of-care tests.


Assuntos
Doenças do Recém-Nascido/diagnóstico , Programas de Rastreamento/métodos , Testes Imediatos , Complicações Infecciosas na Gravidez/diagnóstico , Infecções Estreptocócicas/diagnóstico , Adulto , Antibacterianos/uso terapêutico , Antibioticoprofilaxia , Feminino , Humanos , Recém-Nascido , Doenças do Recém-Nascido/tratamento farmacológico , Doenças do Recém-Nascido/microbiologia , Unidade Hospitalar de Ginecologia e Obstetrícia , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Complicações Infecciosas na Gravidez/microbiologia , Reação em Cadeia da Polimerase em Tempo Real , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/microbiologia , Streptococcus agalactiae/genética , Vagina/microbiologia
5.
Placenta ; 35(6): 425-7, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24731729

RESUMO

Fetal trisomy 21 is associated with elevated maternal serum hCG and its free beta-subunit (hCG-beta) in vivo, and abnormal placental hCG production and glycosylation in vitro. Other maternal serum markers may also be disrupted in major aneuploidies (T21, T18, T13). We evaluated our aneuploidy screening practices, focusing on hCG-beta and hCG glycoforms, and retrospectively analyzed 55 aneuploidy cases diagnosed over a 2 year period, determining maternal serum hCG glycoforms profiles using 2D-electrophoresis. Screening efficiency reached 96.7%. T21 was associated with elevated hCG-beta while T18 presented with diminished serum markers. hCG glycoforms tended to be basic in aneuploidy (mainly T13).


Assuntos
Gonadotropina Coriônica/sangue , Diagnóstico Pré-Natal/métodos , Trissomia/diagnóstico , Adulto , Gonadotropina Coriônica/biossíntese , Gonadotropina Coriônica Humana Subunidade beta/sangue , Transtornos Cromossômicos/sangue , Cromossomos Humanos Par 13 , Cromossomos Humanos Par 18/metabolismo , Síndrome de Down/sangue , Eletroforese em Gel Bidimensional , Feminino , Glicosilação , Humanos , Pessoa de Meia-Idade , Medição da Translucência Nucal , Placenta/metabolismo , Gravidez , Proteína Plasmática A Associada à Gravidez/análise , Estudos Retrospectivos , Síndrome da Trissomia do Cromossomo 13 , Síndrome da Trissomía do Cromossomo 18 , Ultrassonografia Pré-Natal
6.
J Gynecol Obstet Biol Reprod (Paris) ; 43(9): 713-20, 2014 Nov.
Artigo em Francês | MEDLINE | ID: mdl-24268873

RESUMO

OBJECTIVES: To compare pregnancy outcomes after transabdominal chorionic villus sampling using biopsy forceps or needle. MATERIALS AND METHODS: Retrospective bicentric study including all women who had a transabdominal chorionic villus sampling between 2005 and 2009 (172 using biopsy forceps and 160 using needle). The primary endpoint was the rate of fetal loss, after excluding medical abortion due to the result of the biopsy. The secondary endpoint was the rate of premature rupture of the membrane. All cases were reviewed to try to determine the responsibility of the biopsy. RESULTS: The pregnancy outcomes were not different between the two groups: 4 (4.4%) fetal losses in the biopsy forceps group and 6 (7.4%) in the needle group (P=0.52). Only one case (1.2%) of fetal loss can be attributed to the biopsy, using a needle, and none (0%) following a forceps biospy (P=0.29). The rate of premature rupture of the membrane was comparable in the two groups. CONCLUSION: The pregnancy outcomes following chorionic villus sampling using a biopsy forceps or a needle seem comparable.


Assuntos
Biópsia/instrumentação , Amostra da Vilosidade Coriônica/métodos , Resultado da Gravidez/epidemiologia , Biópsia por Agulha , Amostra da Vilosidade Coriônica/efeitos adversos , Feminino , Morte Fetal , Ruptura Prematura de Membranas Fetais/epidemiologia , Ruptura Prematura de Membranas Fetais/etiologia , Humanos , Gravidez , Estudos Retrospectivos , Instrumentos Cirúrgicos
8.
J Gynecol Obstet Biol Reprod (Paris) ; 40(7): 651-6, 2011 Nov.
Artigo em Francês | MEDLINE | ID: mdl-22005046

RESUMO

OBJECTIVE: To compare the performance of two rapid tests for the diagnosis of premature rupture of membranes (PROM) based on the detection of the insulin-like growth factor-binding protein-1 (IGFBP-1) and placental α-microglobulin-1 (PAMG-1) in cervicovaginal secretions. METHODS: A case-control prospective study. Pregnant women between 24 and 41(6/7) weeks' of gestation, consulting for profuse amniotic fluid loss (group 1) or for other reasons without any rupture of membrane (group 2) were included in the study. Successively, AmniSure(®) test (PAMG-1) without speculum, and then Actim™Prom test (IGFBP-1) during speculum examination were performed during the same visit. RESULTS: Eighty subjects (40 in each group) were included between 25(1/7) to 41(1/7) weeks of gestation. AmniSure(®) diagnostic test demonstrated a sensitivity and specificity of 95 % (82.4-99.4) and 94.8 % (79.3-98) respectively and a positive and negative predictive value of 95 % (84.7-100) and 94.8 % (87.9-100) respectively. Actim™Prom diagnostic test demonstrated a sensitivity and specificity of 97.5 % (85.7-100) and 97.4 % (82.4-99.4) respectively and a positive and negative predictive value of 97.5 % (88.5-100) and 97.4 % (92.5-100) respectively. CONCLUSION: Both tests have similar performance to diagnose premature rupture of membranes.


Assuntos
Ruptura Prematura de Membranas Fetais/diagnóstico , Sistemas Automatizados de Assistência Junto ao Leito , Esfregaço Vaginal/métodos , Adulto , alfa-Globulinas/análise , Líquidos Corporais/química , Estudos de Casos e Controles , Feminino , Humanos , Proteína 1 de Ligação a Fator de Crescimento Semelhante à Insulina/análise , Gravidez , Sensibilidade e Especificidade , Vagina/metabolismo , Adulto Jovem
9.
Ultrasound Obstet Gynecol ; 38(2): 229-32, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21800389

RESUMO

Fetal choroid plexus tumors are uncommon. The prognosis is widely variable and depends on the histological findings: papilloma or carcinoma. We report a case of prenatal diagnosis of choroid plexus mass detected by ultrasound at 33 weeks of gestation. Prenatal (T1, T2, T2* and diffusion weighted sequences) magnetic resonance imaging (MRI) was used to rule out a hematoma. Follow-up examination by ultrasound and MRI revealed a significant increase in the volume of the mass, suggesting a diagnosis of malignant tumor. A healthy neonate was delivered by Cesarean section at 38 weeks of gestation. Full surgical excision of the tumor was performed at 20 days after delivery and histological analysis revealed a papilloma.


Assuntos
Carcinoma/diagnóstico , Neoplasias do Plexo Corióideo/diagnóstico , Papiloma do Plexo Corióideo/diagnóstico , Diagnóstico Pré-Natal/métodos , Adulto , Carcinoma/embriologia , Carcinoma/patologia , Neoplasias do Plexo Corióideo/embriologia , Neoplasias do Plexo Corióideo/patologia , Diagnóstico Diferencial , Feminino , Humanos , Recém-Nascido , Imageamento por Ressonância Magnética , Masculino , Papiloma do Plexo Corióideo/embriologia , Papiloma do Plexo Corióideo/patologia , Gravidez , Prognóstico , Ultrassonografia Pré-Natal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA